Literature DB >> 8834881

MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci.

M A Visalli1, M R Jacobs, P C Appelbaum.   

Abstract

MIC and time-kill methods were used to test the activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible, -intermediate, and -resistant pneumococci. The MIC of penicillin for penicillin-susceptible strains was 0.016 micrograms/ml, those for intermediate strains were 0.25 to 1.0 microgram/ml, and those for resistant strains were 2.0 to 4.0 micrograms/ml. Of the four quinolones tested, DU-6859a had the lowest MIC (0.064 micrograms/ml), followed by sparfloxacin (0.25 to 0.5 micrograms/ml) and levofloxacin and ciprofloxacin (both 1.0 to 4.0 micrograms/ml). Vancomycin inhibited all strains at MICs of 0.25 to 0.5 micrograms/ml. The MICs of imipenem and cefotaxime for penicillin-susceptible, -intermediate, and -resistant strains were 0.004 to 0.008, 0.008 to 0.032, and 0.25 micrograms/ml and 0.016, 0.125 to 0.5, and 2.0 micrograms/ml, respectively. DU-6859a was bactericidal at eight times the MICs (0.5 micrograms/ml) for seven of the nine strains after 4 h and bactericidal for all nine strains after 6 h at eight times the MICs and after 12 h at two times the MICs. By comparison, sparfloxacin, the next most active quinolone, was uniformly bactericidal at two times the MICs only after 24 h, with little activity after 2 h. Levofloxacin and ciprofloxacin were bactericidal against all strains after 12 h at eight times the MICs and against all strains at 24 h at four times the MICs. Imipenem was bactericidal against all strains, at concentrations exceeding the MICs, after 24 h. Cefotaxime was also uniformly bactericidal only after 24 h of incubation at two times the MICs. Vancomycin, despite having uniformly low MICs for all strains irrespective of their penicillin susceptibility, was uniformly bactericidal only at two times the MICs after 24 h.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8834881      PMCID: PMC163117     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group.

Authors:  J S Spika; R R Facklam; B D Plikaytis; M J Oxtoby
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

Review 2.  Management of penicillin-resistant pneumococcal infections.

Authors:  I R Friedland; G R Istre
Journal:  Pediatr Infect Dis J       Date:  1992-06       Impact factor: 2.129

Review 3.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

4.  Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis.

Authors:  R Munoz; J M Musser; M Crain; D E Briles; A Marton; A J Parkinson; U Sorensen; A Tomasz
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

Review 5.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

6.  Susceptibility of penicillin-resistant pneumococci to eighteen antimicrobials: implications for treatment of meningitis.

Authors:  D J Tweardy; M R Jacobs; W T Speck
Journal:  J Antimicrob Chemother       Date:  1983-08       Impact factor: 5.790

7.  Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.

Authors:  K Sato; K Hoshino; M Tanaka; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

8.  Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

9.  Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States.

Authors:  L K McDougal; R Facklam; M Reeves; S Hunter; J M Swenson; B C Hill; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

10.  Evaluation of vancomycin for therapy of adult pneumococcal meningitis.

Authors:  P F Viladrich; F Gudiol; J Liñares; R Pallarés; I Sabaté; G Rufí; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

View more
  27 in total

1.  Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents.

Authors:  Glenn A Pankuch; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  Antipneumococcal activity of BMS 284756 compared to those of six other agents.

Authors:  Glenn A Pankuch; Kensuke Nagai; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.

Authors:  E A Coyle; G W Kaatz; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  Shana M Gunderson; Robert A Hayes; John P Quinn; Larry H Danziger
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

5.  Antipneumococcal activities of gemifloxacin compared to those of nine other agents.

Authors:  T A Davies; L M Kelly; G A Pankuch; K L Credito; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

6.  In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model.

Authors:  Yuichi Fukuda; Katsunori Yanagihara; Hideaki Ohno; Yasuhito Higashiyama; Yoshitsugu Miyazaki; Kazuhiro Tsukamoto; Yoichi Hirakata; Kazunori Tomono; Yohei Mizuta; Takayoshi Tashiro; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

7.  Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.

Authors:  Klaudia Kosowska-Shick; Kim Credito; Glenn A Pankuch; Gengrong Lin; Bülent Bozdogan; Pamela McGhee; Bonifacio Dewasse; Dong-Rack Choi; Jei Man Ryu; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

8.  Comparative antipneumococcal activities of sulopenem and other drugs.

Authors:  Klaudia Kosowska-Shick; Lois M Ednie; Pamela McGhee; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

9.  Antipneumococcal activity of dalbavancin compared to other agents.

Authors:  Gengrong Lin; Kathy Smith; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

10.  Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.

Authors:  Lois M Ednie; Glenn Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.